These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9694139)

  • 1. Treatment of detrusor instability with oxybutynin rectal suppositories.
    Winkler HA; Sand PK
    Int Urogynecol J Pelvic Floor Dysfunct; 1998; 9(2):100-2. PubMed ID: 9694139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in anticholinergic therapy delivery systems.
    Davila GW
    Geriatrics; 2002 May; 57 Suppl 1():29-34. PubMed ID: 12040601
    [No Abstract]   [Full Text] [Related]  

  • 4. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical oxybutynin: practicalities of clinical use.
    Guerrero K; Emery S; Owen L; Rowlands M
    J Obstet Gynaecol; 2006 Feb; 26(2):141-3. PubMed ID: 16483973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.
    Leung HY; Yip SK; Cheon C; Liu YS; Lau J; Wong HK; Chung KH
    BJU Int; 2002 Sep; 90(4):375-80. PubMed ID: 12175392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial.
    Tincello DG; Adams EJ; Sutherst JR; Richmond DH
    BJU Int; 2000 Mar; 85(4):416-20. PubMed ID: 10691817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia.
    O'Flynn KJ; Thomas DG
    Br J Urol; 1993 Nov; 72(5 Pt 1):566-70. PubMed ID: 10071538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.
    Saito M; Watanabe T; Tabuchi F; Otsubo K; Satoh K; Miyagawa I
    Int J Urol; 2004 Aug; 11(8):592-6. PubMed ID: 15285747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
    Versi E; Appell R; Mobley D; Patton W; Saltzstein D
    Obstet Gynecol; 2000 May; 95(5):718-21. PubMed ID: 10775736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxybutynin hydrochloride in the management of detrusor instability.
    Primus G; Pummer K
    Int Urol Nephrol; 1990; 22(3):243-8. PubMed ID: 2210980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical oxybutynin hydrochloride in the treatment of urge incontinence in the elderly].
    Mizunaga M; Miyata M; Kaneko S; Taniguchi N; Yachiku S; Chiba K; Osanai H; Fujisawa M
    Nihon Hinyokika Gakkai Zasshi; 1996 Jun; 87(6):923-7. PubMed ID: 8753011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Topical administration of oxybutynin hydrochloride in women with urge incontinence. Results of a prospective randomized double-blind study].
    Enzelsberger H; Kurz C; Helmer H; Mittermayer F
    Geburtshilfe Frauenheilkd; 1995 May; 55(5):240-3. PubMed ID: 7607378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
    Lose G; Nørgaard JP
    BJU Int; 2001 Jun; 87(9):767-73. PubMed ID: 11412211
    [No Abstract]   [Full Text] [Related]  

  • 18. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.
    Yarker YE; Goa KL; Fitton A
    Drugs Aging; 1995 Mar; 6(3):243-62. PubMed ID: 7620236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical oxybutynin chloride: experience with 42 patients.
    Weese DL; Roskamp DA; Leach GE; Zimmern PE
    Urology; 1993 Jun; 41(6):527-30. PubMed ID: 8516987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of oxybutynin on sensory urgency as compared with that on motor urgency.
    Hashimoto K; Ohnishi N; Esa A; Sugiyama T; Park Y; Kurita T
    Urol Int; 1999; 62(1):12-6. PubMed ID: 10436424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.